scholarly journals A case of type 1 diabetes mellitus caused by low-dose, long-term natural interferon α therapy for a patient with chronic hepatitis C

Kanzo ◽  
2011 ◽  
Vol 52 (6) ◽  
pp. 335-343
Author(s):  
Takeo Hayashi ◽  
Mosaburo Kainuma ◽  
Hiroaki Taniai ◽  
Masayuki Murata ◽  
Kyoko Okada ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Type 1 Diabetes Mellitus ◽  
Chronic Hepatitis C ◽  
Low Dose ◽  
Interferon Α

scholarly journals Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review

2011 ◽  
Vol 4 ◽  
pp. CMED.S7815 ◽  
Author(s):  
Reiko Oka ◽  
Naoki Hiroi ◽  
Rika Shigemitsu ◽  
Mariko Sue ◽  
Yasuo Oshima ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Chronic Hepatitis ◽  
Blood Glucose ◽  
Hepatitis C ◽  
Type 1 Diabetes Mellitus ◽  
Chronic Hepatitis C ◽  
Glycosylated Hemoglobin ◽  
Pegylated Interferon

Combined pegylated interferon (PEG-IFN)+ribavirin (RBV) therapy has been used as a primary treatment for chronic hepatitis C. However, IFN-induced autoimmune disease, including type 1 diabetes mellitus, has been highlighted as one of the problems with this therapy. Here we report the case of a patient who developed type 1 diabetes mellitus during combined PEG-IFN+RBV therapy for hepatitis C but who showed no exacerbation of diabetes despite continued use of IFN. A 63-year-old man with chronic hepatitis C and a nonresponder to previous IFNα treatments, was admitted to our hospital because of excessive thirst, polydipsia, and polyuria 24 weeks after the start of PEG-IFNα+RBV therapy. High levels of blood glucose and glycosylated hemoglobin and low levels of C-peptide and immunoreactive insulin were observed. The serum antiglutamic acid decarboxylase antibody titer was 27,700 U/mL. We diagnosed IFN-induced type 1 diabetes mellitus; however PEG-IFNα+RBV therapy was continued for 48 weeks. Serum HCV remains negative five years after this treatment. Intensive insulin therapy was started immediately after the diagnosis of type 1 diabetes. Although the patient initially required 22 U/day of insulin, the dosage could be gradually reduced after completion of PEG-IFNα+RBV therapy and blood glucose remained well controlled. Prediction of onset of type 1 diabetes mellitus on the basis of baseline measurement of pancreas-associated autoantibodies is difficult. Therefore, it would be advisable to consider the possibility of onset of type 1 diabetes mellitus in all patients receiving IFN+RBV therapy.

Onset of type 1 diabetes mellitus during peginterferon ??-2b plus ribavirin treatment for chronic hepatitis C

2006 ◽  
Vol 18 (6) ◽  
pp. 689-692 ◽  
Author(s):  
Raffaele Cozzolongo ◽  
Corrado Betterle ◽  
Paolo Fabris ◽  
Maria Paola Albergoni ◽  
Elsa Lanzilotta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Type 1 Diabetes Mellitus ◽  
Chronic Hepatitis C

scholarly journals Type 1 Diabetes Mellitus Provoked by Peginterferon α-2b Plus Ribavirin Treatment for Chronic Hepatitis C

2008 ◽  
Vol 47 (8) ◽  
pp. 747-749 ◽  
Author(s):  
Junichirou Tanaka ◽  
Kazushi Sugimoto ◽  
Katsuya Shiraki ◽  
Tetsuya Beppu ◽  
Kentarou Yoneda ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Type 1 Diabetes Mellitus ◽  
Chronic Hepatitis C ◽  
Peginterferon Α
Sign in / Sign up

Export Citation Format

Share Document